Biocompatible peritoneal dialysis fluids: clinical outcomes

Area of Science:

• Nephrology
• Biomaterials Science
• Clinical Medicine

Background:

• Peritoneal dialysis (PD) is a preferred home dialysis treatment with advantages in survival and cost-effectiveness.
• However, PD uptake is limited by technique failure due to infections and ultrafiltration issues, often caused by "unphysiologic" PD fluid composition.
• Peritoneal injury from PD fluids is a key barrier to wider PD implementation.

Purpose of the Study:

• To review randomized controlled trials (RCTs) evaluating the clinical outcomes of using biocompatible PD fluids.
• To assess the impact of advanced PD fluid formulations on patient health and treatment efficacy.

Main Methods:

• Systematic review of randomized controlled trials.
• Analysis of studies investigating biocompatible PD fluids with neutral pH, low glucose degradation products, and bicarbonate buffer.
• Evaluation of effects on host cell defense, peritoneal membrane integrity, and cytokine profiles in preclinical studies.

Main Results:

• Preclinical data suggest biocompatible PD fluids improve host cell defense and peritoneal membrane integrity.
• These fluids may positively influence the peritoneal cytokine profile.
• Clinical outcome data from RCTs are needed to confirm these benefits.

Conclusions:

• Biocompatible PD fluids represent a promising advancement in dialysis therapy.
• Further clinical research is essential to confirm their efficacy in improving patient outcomes and overcoming PD limitations.
• Wider adoption of biocompatible PD fluids could enhance the long-term viability of peritoneal dialysis.